Cisplatin, Gemcitabine and Bevacizumab in Combination for Metastatic Transitional Cell Cancer
Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
Cisplatin is a very important agent for the treatment of TCC as it has a single agent
response rate of approximately 15%. However, it has been most important as a part of
combination chemotherapy, MVAC initially and now in combination with gemcitabine. Single
agent gemcitabine has demonstrated an overall response rate (ORR) of approximately 25%,
including some complete responses (CR), with minimal toxicity in patients with advanced
bladder cancer. Bevacizumab, a murine anti-human VEGF monoclonal antibody, has been advanced
for use in combination with cytotoxic chemotherapy to delay time to disease progression in
patients with metastatic solid tumors.
This trial is designed to further assess the efficacy, safety and tolerability of this
regimen in this patient population.
Phase:
Phase 2
Details
Lead Sponsor:
Christopher Sweeney, MBBS
Collaborators:
Eli Lilly and Company Genentech, Inc. Hoosier Cancer Research Network Walther Cancer Institute